Background. We previously reported attenuation of serum OVA-specific IgE levels and of lymphocyte-derived IL-4, both nominal markers of allergic immunity, following injection of a combination of homologous (mouse) polyclonal anti-idiotypic immunoglobulin (Ig) and immune Ig in BALB/c mice. We predicted this might generalize to other species and using heterologous mixtures of Igs. This was assessed in mice using OVA sensitization in the presence of human Igs as a source of both anti-idiotype Ig and immune Ig and in dogs with peanut butter-induced allergic responses. Methods. Eight-week-old BALB/c mice received OVA immunization and 5 weekly injections of immune Ig or anti-idiotype Ig from either homologous (mouse) or heterologous (human) sources. Five-month-old Beagles received weekly topical exposure (on the abdomen) to peanut butter and treatment with pooled dog Ig and dog antirabies immune Ig, or a combination of human IMIG and human anti-Tet. All mice/dogs thereafter received a final allergen challenge, and serum IgG, IgE, and allergen-induced IL-2/IL-4 and IL-31 production in 72 hr cultures was measured. Results. In mice attenuation of OVA-induced allergy (IgE-specific Ig and OVA-induced IL-4) was seen using both mouse and human Ig mixtures, without effect on OVA serum IgG or OVA-induced IL-2. Attenuation of concanavalin A- (ConA-) induced IL-4 : IL-2 production and of peanut butter-induced IL-4 and IL-31 was seen in dogs receiving combinations of both heterologous and homologous immune Igs and anti-idiotype Igs, with no decline in IL-2 production. Allergen-specific IgE/IgG was not detectable in dog serum, but there was a trend to lower total serum IgE levels (and decreased IgE : IgG ratios). Conclusion. Homologous and heterologous combinations of polyclonal IMIG and immune Ig attenuate allergic responses in mice and dogs. This treatment protocol represents a novel approach which can be adapted for allergic desensitization in veterinary and human use.

中文翻译：

---

联合 IMIG 和免疫 Ig 可减轻比格犬的过敏反应。

背景。我们之前报道了在 BALB 中注射同源（小鼠）多克隆抗独特型免疫球蛋白（Ig）和免疫 Ig 的组合后血清 OVA 特异性 IgE 水平和淋巴细胞衍生的 IL-4 的减弱，这两者都是过敏性免疫的名义标志物/c 老鼠。我们预测这可能会推广到其他物种并使用 Igs 的异源混合物。在人 Igs 作为抗独特型 Ig 和免疫 Ig 的来源的情况下，使用 OVA 致敏小鼠和具有花生酱诱导的过敏反应的狗对此进行了评估。方法. 八周大的 BALB/c 小鼠接受 OVA 免疫和每周 5 次注射来自同源（小鼠）或异源（人）来源的免疫 Ig 或抗独特型 Ig。五个月大的比格犬每周接受一次花生酱的局部暴露（腹部），并用混合的狗 Ig 和狗抗狂犬病免疫 Ig 或人类 IMIG 和人类抗 Tet 的组合进行治疗。此后，所有小鼠/狗接受最后的过敏原攻击，并测量了 72 小时培养物中血清 IgG、IgE 和过敏原诱导的 IL-2/IL-4 和 IL-31 的产生。结果. 在小鼠中，使用小鼠和人 Ig 混合物均观察到 OVA 诱导的过敏（IgE 特异性 Ig 和 OVA 诱导的 IL-4）减弱，对 OVA 血清 IgG 或 OVA 诱导的 IL-2 没有影响。伴刀豆球蛋白 A- (ConA-) 诱导的 IL-4 减弱：在接受异源和同源免疫 Igs 和抗独特型 Igs 组合的狗中观察到 IL-2 产生和花生酱诱导的 IL-4 和 IL-31， IL-2 产量没有下降。在狗血清中未检测到过敏原特异性 IgE/IgG，但总血清 IgE 水平有降低的趋势（并且 IgE：IgG 比率降低）。结论. 多克隆 IMIG 和免疫 Ig 的同源和异源组合减弱了小鼠和狗的过敏反应。该治疗方案代表了一种新方法，可适用于兽医和人类使用的过敏脱敏。